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Topotecan is currently approved for relapsed small-cell lung cancer and ovarian cancer. Topotecan’s efficacy in the second-line setting
and novel mechanism of action suggest broad antitumour activity. We utilised a clinically validated, cell-death, ex vivo assay in human
tumour explants to examine the activity profile of topotecan alone and in combination with other antitumour agents. Serial dilutions
of topotecan alone and in combination with other cytotoxic agents were applied to biopsy specimens of non-small-cell lung cancer
(NSCLC) and breast, colon, and prostate cancers. Dose–response curves were interpolated to provide 50% lethal concentrations
(LC50). The degree of synergy (by median effect) and normalised Z-scores (raw scores converted to relative activity distributed
around the mean) were then computed. Single-agent activity was observed for topotecan in all four tumour types. In 57
chemotherapy-naive specimens, NSCLC revealed the highest activity, demonstrated by the lowest LC50 value (0.2670.06mgml
 1;
P¼0.002). Overall, previously treated and chemotherapy-naive specimens revealed no significant differences in mean LC50’s. Synergy
was observed for several combinations, including topotecan plus cisplatin in prostate and for topotecan plus 5-fluorouracil in breast
cancers. The Z-score analyses conducted suggest activity for previously unexplored drug regimens, including topotecan plus 5-
fluorouracil, vinorelbine, and mitomycin-C in NSCLC and breast cancer. Phase II studies are underway to determine the degree to
which these ex vivo findings will translate into improved clinical results.
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Topotecan, a semisynthetic, water-soluble derivative of camp-
tothecin, is an inhibitor of topoisomerase I (Kingsbury et al, 1991).
This derivative is more stable, has increased solubility, a shorter
half-life, and decreased toxicity compared with its parent
compound (Verweij et al, 1993; Burke and Mi, 1994; Rothenberg,
1997). Topoisomerase I is a nuclear enzyme that relieves torsional
strain on supercoiled DNA and creates single-strand breaks during
DNA replication. Topotecan prevents topoisomerase I from
repairing the cleaved DNA, which results in double-stranded
DNA breaks and eventually apoptosis. The unique mechanism of
action of topotecan and lack of clinical crossresistance with other
antineoplastic compounds suggest that topotecan has the potential
for broad antitumour activity.
The activity of topotecan has been demonstrated in several
open-label, randomised phase II and III trials. Currently,
topotecan is approved for the treatment of relapsed small-cell
lung cancer (SCLC) (Eckardt et al, 1996; Ardizzoni et al, 1997;
Depierre et al, 1997; von Pawel et al, 1999, 2001) and ovarian
cancer (Creemers et al, 1996; Kudelka et al, 1996; ten Bokkel
Huinink et al, 1997; Bookman et al, 1998; Hoskins et al, 1998;
McGuire et al, 2000). Although topotecan is typically given in a 30-
min intravenous (i.v.) infusion on days 1–5 of a 21-day course,
other clinical schedules have been investigated, including 21-day
continuous i.v. infusion (Hochster et al, 1999), 3-day administra-
tion (Brown et al, 2000), single-day administration every 21 days
(Wall et al, 1992), weekly bolus (Homesley et al, 2001), and weekly
24-h continuous i.v. infusion (Hoskins et al, 1998). In addition, an
oral formulation of topotecan has also been investigated in SCLC
(von Pawel et al, 2001) and ovarian cancer (Clarke-Pearson et al,
2001). Preliminary reports indicate that topotecan also has activity
in non-small-cell lung cancer (NSCLC) (Lynch et al, 1994; Perez-
Soler et al, 1996), cervical cancer (Fiorica et al, 2002), and
haematologic malignancies (Beran et al, 1998). Additional studies
are required to determine the activity of topotecan in other
cancers.
Topotecan activity also suggests potential for synergy in
combination with other cytotoxic agents. The predictable toxicity
profile of topotecan makes it feasible to combine topotecan with
other agents with nonoverlapping toxicities. Topotecan has been
investigated in doublet and triplet combinations with several
agents, including cisplatin, paclitaxel, and etoposide (Ardizzoni
et al, 1999; Frasci et al, 1999; Hainsworth et al, 1999; Jacobs et al,
1999; O’Neill et al, 2001; Fiorica et al, 2002). Randomised trials are
underway in several diseases to evaluate the efficacy of topotecan
in combination with other agents.
Ex vivo analyses of human tumour primary cultures can provide
disease-specific drug activity profiles and powerful insights useful
in the development of phase I/II trials. The present study applied
an ex vivo assay, based on the delayed loss of membrane integrity,
to investigate the clinical potential of topotecan in human tumour
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sbiopsy specimens other than relapsed SCLC and ovarian cancer.
Although earlier laboratory assays based on drug-induced growth
inhibition (e.g. H3*-thymidine incorporation, clonogenic) have
consistently failed to provide clinically relevant information, newer
methods that incorporate cell-death measures as surrogates of
drug-induced apoptosis have been shown to correlate with
response, time to progression, and survival in human haemato-
logic and solid tumours (Bosanquet et al, 1999; Cortazar and
Johnson, 1999; Nagourney et al, 2000, 2003). The realisation that
most chemotherapeutic agents exert their cytotoxic effects through
apoptosis (Reed, 1999) supports the use of cell-death assay in the
study of topotecan’s antitumour activity in human neoplasms.
The principal focus of this study was the investigation of
topotecan activity in biopsies of previously untreated NSCLC and
breast, colorectal, and prostate carcinomas. We also assessed the
synergy of topotecan in combination with other antineoplastic
agents and compared the activity of topotecan in chemotherapy-
naive vs previously treated specimens. Additional analyses
compared the activity of topotecan with that of irinotecan, the
related topoisomerase I inhibitor, in parallel studies.
MATERIALS AND METHODS
Tissue procurement and tumour-cell preparation
Patients undergoing surgical procedures for the management of
NSCLC and breast, colorectal, or prostate cancers were offered the
opportunity to participate in the study. All patients provided
written informed consent allowing the release of tumour biopsy
specimens for laboratory analysis. At the time of surgical
exploration, tumour tissues removed from the patients were
processed sterilely by the Department of Pathology at the Long
Beach Memorial Medical Centre (Long Beach, CA, USA). After
histologic diagnostic evaluations, the tissue samples were placed in
sterile RPMI 1640 media containing 2mML -glutamine, 15% fetal
calf serum, 100IUml
 1 penicillin, and 100mgml
 1 streptomycin
(modified RPMI 1640), and were submitted directly to our
laboratory. Samples obtained after hours were maintained at 41C
until processed (always o24h). This study was approved by the
Long Beach Memorial Medical Centre Human Subjects Committee.
Tumour specimens were mechanically disaggregated by sterile
mincing with scalpels. Specimens were then incubated for 2h in
0.8% collagenase IV and 0.002% DNaseI. Cells were isolated by
density centrifugation over Ficoll–Hypaque, washed, and then
resuspended in modified RPMI 1640. Cell suspensions were
adjusted to 1 10
6 cellsml
 1 and distributed into 96-well
polypropylene culture plates (90mlwell
 1). Serial dilutions of
drugs and drug combinations in 10ml volumes were added, and the
plates were incubated at 371Ci n6 %C O 2 in a sterile, humidified
environment for 72h as described in the next section.
Drug exposure and measurement of cell viability
The dose-dependent cytotoxicity of drugs was investigated using a
five-point dose–response curve. Serial dilutions of cytotoxic drugs
were prepared in 0.15 M NaCl, and 10ml of a drug solution was
added to each well. Cells were incubated for 72h with saline vehicle
control (0.15 M NaCl) or in the presence of topotecan (range, 0.03–
0.92mgml
 1), alone or in combination at a fixed ratio in serial
dilution with 5-fluorouracil (5-FU; range, 3.1–100mgml
 1),
cisplatin (range, 0.2–6.6mgml
 1), doxorubicin (range, 0.04–
1.2mgml
 1), gemcitabine (range, 8.2–263mgml
 1), mitomycin-C
(range, 0.04–1.2mgml
 1), mitoxantrone (range, 0.03–1.0mgml
 1),
nitrogen mustard (range, 0.17–5.4mgml
 1), oxaliplatin (range,
0.3–10mgml
 1), paclitaxel (range, 1.6–50mgml
 1), or vinorelbine
(range, 0.3–10mgml
 1). After 72h, 10ml of phosphate-buffered
saline containing 0.5% nigrosin-B and 1% Fast Green and 37500
glutaraldehyde-fixed avian red blood cells (internal standard) were
added to each well, and the samples were gently agitated to
facilitate mixing. After 10min, samples were aspirated and
centrifuged onto a glass slide using a modified cytospin cassette.
Air-dried samples were counterstained with modified haematox-
ylin and eosin. Tumour cell viability was determined as the ratio of
living tumour cells over simultaneously counted avian red blood
cells. Cell survival of drug-treated samples was expressed as a
percentage of saline control values.
Calculation of LC50, synergy, and Z-score
The 50% lethal concentration (LC50) values were calculated using a
least-squares line of best-fit generated from the five-point
concentration curve, with the LC50 values interpolated from the
curve. Synergy was determined using the median effect technique
(Chou and Talalay, 1987, pp 37–64). In brief, dose–response
curves and LC50 values were generated for topotecan both as a
single agent and in combination with other agents. Comparison of
the topotecan single-agent dose–response curves with the
combination dose–response curves for a given tumour type
allowed the determination of synergy, additivity, subadditivity, or
antagonism. The term synergy only applied to tumour samples
with 100% of the points on the combination dose–response curves
falling above the line of additivity, while partial synergy applied to
samples for which 450% of the points on the dose–response
curve were above the line of additivity.
The overall mean LC50 (LC50T) and s.e.m. for all tumour types
(s.e.m T) within our laboratory database were utilised to calculate
Z-scores by the following formula:
ðLC50sample   LC50TÞ
s:e:m:T
The use of inferential statistics is predicated upon the central limit
theorem (Feinstein, 1998), a fundamental sampling theorem that
states that the distribution of a sample population is unimportant
so long as the samples are drawn randomly in sufficient numbers
from a parent population whose distribution need not have a
normal (Gaussian) distribution (Hays, 1994).
By normalising the LC50 values for each single agent and/or
combination around the mean LC50 values, samples found to be
more resistant than average fell to the right of the mean, whereas
those that were more sensitive than average fell to the left of the
mean. This Z-score transformation is routinely used in the US by
the National Cancer Institute for studies comparing microarray
data and other analyses (Cheadle et al, 2003). It has been
incorporated into the COMPARE statistical program (Shi et al,
1998), and into the latest version of the National Cancer Institute’s
public access MAExplorer bioinformatics tool (Lemkin et al, 2000).
STATISTICAL METHODS
Statistical analysis of the study data was carried out using the
analysis of variance program from the Statistical Package for the
Social Sciences (Levine, 1991). The LC50 means for single-agent
topotecan in untreated biopsies were compared across tumour
types, with the criterion for statistical significance set at Pp0.05.
For comparisons of in vitro activity of topotecan in combination
with other agents, LC50 values were normalised into Z-scores (with
the mean set to 0 and variance from the mean in s.e.m. units of 1)
(Kirk, 1982). This permitted direct comparisons of the sensitivity
vs resistance of drug combinations across tumour types. Using
these normalised LC50 values, graphic representations were
generated depicting on the left side of the mean those samples
more sensitive than average to drug combinations (negative
range), and on the right side of the mean those more resistant
than average to drug combinations (positive range). Finally, the
activity of topotecan vs irinotecan in tumour specimens was
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sassessed using a scatter gram graph and was statistically compared
using the Pearson product-moment correlation from the same
statistical package.
RESULTS
Activity of single-agent topotecan
In aggregate, our topotecan database includes a total of 697
analyses, of which 380 are from NSCLC, and breast, colon, and
prostate cancer biopsies that have been studies against single-agent
topotecan. These include 149 specimens from chemotherapy-naive
patients (untreated specimens) and 231 specimens from previously
treated patients (previously treated specimens).
To assess the effect of prior chemotherapy exposure on the
activity of topotecan, the LC50 values of topotecan in cells obtained
from previously treated specimens were compared with those from
untreated specimens (Figure 1). The mean LC50 value for all
previously treated specimens was only marginally higher than that
for the untreated specimens. However, when comparing previously
treated LC50 values with untreated LC50 values within tumour
types, several trends emerged. For instance, a comparison between
the LC50 values of 135 previously treated breast cancer specimens
with 33 untreated breast cancer specimens indicated a trend
toward greater sensitivity in the previously treated specimens. The
opposite trend was observed in colon cancer and NSCLC speci-
mens. By rank order, previously untreated NSCLC specimens
exhibited the lowest LC50 value (P¼0.002), whereas previously
untreated prostate cancer specimens had the highest LC50 value,
suggesting that NSCLC and breast cancer might be better targets
for topotecan than colon or prostate cancers.
To address concerns that prior exposure to chemotherapy might
pose a confounding variable, we procured 86 tumour specimens
from previously untreated patients to conduct formal drug
response and combination analyses. Viable tumour cells were
successfully isolated from 74 (86%) of these specimens. Of 74
specimens, 57(77%), including 14 NSCLC and 18 breast, 13
prostate, and 12 colon cancer specimens, provided adequate cell
yield for complete single-agent and a combination-agent analyses.
Of the 74 specimens, 17(23%) provided adequate cell yield for
partial analyses. The LC50 value (7s.e.m.) for single-agent
topotecan in all 57 tumours was 0.4370.04mgml
 1. The LC50
values for each tumour type are shown in Table 1. The NSCLC
samples demonstrated the lowest LC50 value at 0.2670.06mgml
 1
(P¼0.002), suggesting that NSCLC is a potential target for
topotecan treatment.
Synergy of topotecan combinations
The mechanism of action of topotecan suggests that combinations
with other cytotoxic agents may provide increased antitumour
activity. To assess this potential, a variety of topotecan–drug
combinations were investigated for activity and degree of synergy.
The LC50 values for topotecan in combination with other agents, at
fixed drug ratios, and the degree of synergy for the different drug
combinations by tumour type are provided in Table 2. It is worth
noting that the degree of synergy varied by drug combination and
tumour type.
Z-scores of topotecan combinations
Ex vivo drug concentrations were based on the clinically correlated
database. Concentration ranges, by drug, varied by as much as
three orders of magnitude. To compare antitumour activity in
highly disparate concentration ranges directly, raw LC50 values
were normalised using Z-scores, as summarised in Table 2 and
illustrated in Figures 2 and 3. The data used in the generation of
the s.e.m. values were obtained in previously untreated solid
tumours in the laboratory database. These included NSCLC, colon,
gastric, breast, ovarian, pancreatic, and uterine cancer specimens,
ranging in number from 17 (mitoxantrone) to 53 (vinorelbine)
with a median of 35 analyses per drug combination. A variety of
combination regimens fell within the sensitive range of Z-scores
for breast cancer and NSCLC tumour samples. The combination of
doxorubicin and topotecan revealed significantly different Z-
scores between breast and prostate cancer (Po0.001). Likewise, a
comparison of prostate cancer, colon cancer, and NSCLC samples
revealed significant differences in Z-scores across these tumour
types for the combination of topotecan and oxaliplatin (Po0.01).
Analyses of variance conducted across the four tumour types
revealed significant differences in Z-scores for the topotecan/
cisplatin combination (Po0.05). Finally, the topotecan/mitomy-
cin-C combination resulted in significantly different Z-scores
between NSCLC and colon cancer tumour samples (Po0.01). Only
two combination regimens (topotecan/cisplatin and topotecan/
nitrogen mustard) demonstrated Z-scores in the sensitive range in
prostate cancer samples. None of the drug combinations tested on
colon cancer samples had Z-scores within the sensitive range.
Topotecan vs irinotecan
A unique advantage of these ex vivo analyses is their ability to
compare drugs in parallel studies conducted on individual patient
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Figure 1 LC50 values for single-agent topotecan in tumour biopsies
taken from untreated and previously treated patients in the master
database. Tumour biopsies from patients with breast cancer, colon cancer,
NSCLC, or prostate cancer were incubated with various concentrations of
topotecan, and the LC50 values were calculated. The numbers in
parentheses indicate the number of samples for the indicated drug
combination.
Table 1 LC50 (mgml
 1) values for single-agent topotecan in untreated biopsies by tumour type
All tumours, n¼57 Breast, n¼18 Colon, n¼12 NSCLC, n¼14 Prostate, n¼13
Mean7s.d. 0.4370.30 0.4070.25 0.4770.31 0.2670.22* 0.6370.22
Median 0.35 0.30 0.40 0.20 0.50
LC50¼50% lethal concentration; NSCLC¼non-small-cell lung cancer; s.d.¼standard deviation. *Po0.002. (t-test, comparing NSCLC to other tumour types).
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stumour specimens. Irinotecan, another topoisomerase I inhibitor,
is a prodrug activated by carboxylesterase to form the active
metabolite SN38. While spontaneous degradation or activation by
carboxylesterases present in culture media is known to occur, and
provides cytotoxic activity in vitro, some variability between
irinotecan and topotecan would be expected based on topotecan’s
direct cytotoxic actions. When we directly compared the activity of
topotecan against that of irinotecan in 239 chemonaive and
previously treated human tumour specimens, there was a
significant correlation between the LC50 values for topotecan vs
irinotecan (Po0.0005). At the time of initial calculation, a portion
of the LC50 values were rounded to the nearest 0.1mgml
 1 value.
DISCUSSION
The clinical efficacy and favourable safety profile of topotecan in
the treatment of relapsed SCLC and ovarian cancer patients, and
topotecan’s novel mechanism of action have prompted investiga-
tions into its use in other solid tumours. Ex vivo analyses, based on
clinically validated end points, can identify disease-specific drug
activity profiles and offer a rational approach to drug develop-
ment. We applied ex vivo analyses to evaluate the activity of single-
agent topotecan and topotecan combinations in human NSCLC
and breast, colon, and prostate cancer specimens.
Ex vivo topotecan activity was highest for NSCLC and breast
cancer specimens and lowest for prostate and colon cancer
Table 2 In vitro activity of topotecan in combination with other agents
Diagnosis (n) Mean LC50 (lgml
 1) Synergy *(%) Z-score
5-fluorouracil
Breast (9) 13.21 57  1.70
Colon (12) 18.37 15 +0.46
NSCLC (3) 25.00 0 +3.25
Cisplatin
Breast (9) 1.44 13 +2.31
Colon (11) 1.67 17 +4.17
NSCLC (20) 0.88 31  2.28
Prostate (4) 0.88 75  2.32
Doxorubicin
Breast (17) 0.34 25  1.76
Prostate (14) 0.61 25 +0.082
Gemcitabine
Breast (10) 51.10 0  1.32
Colon (11) 65.18 27 +1.25
NSCLC (18) 45.61 7  2.32
Prostate (10) 81.0 0 +4.13
Mitomycin-C
Colon (10) 0.96 40 +3.88
NSCLC (16) 0.45 38  2.43
Mitoxantrone
Breast (9) 0.32 17  1.10
Prostate (8) 0.46 25 +1.24
Nitrogen mustard
Breast (17) 1.11 25 +0.24
NSCLC (3) 0.97 0  0.98
Prostate (4) 1.05 25  0.28
Oxaliplatin
Colon (10) 2.59 22 +0.76
NSCLC (16) 1.53 8  3.13
Prostate (10) 3.52 20 +4.18
Paclitaxel
Breast (13) 6.73 33  0.38
NSCLC (19) 7.98 0 +1.59
Vinorelbine
Breast (13) 2.04 25  1.36
Colon (11) 2.96 27 +2.76
NSCLC (19) 1.82 13  2.33
Prostate (10) 3.05 25 +3.15
*Defined as the percentage of tumour samples that demonstrated 100% synergy as
described in Materials and Methods section. LC50¼50% lethal concentration;
NSCLC¼non-small-cell lung cancer.
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Figure 2 Z-scores of topotecan combination regimens in four tumour
types. Z-scores of topotecan in biopsies from patients with breast cancer
(open), colon cancer (dark grey), NSCLC (black), and prostate cancer (light
grey). The numbers in parentheses indicate the number of samples for the
indicated drug combination. NSCLC¼non-small-cell lung cancer; 5-
FU¼5-fluorouracil; CDDP¼cisplatin; DOX¼doxorubicin;
GEM¼gemcitabine; MITX¼mitoxantrone; NAV¼vinorelbine; NM¼ni-
nitrogen mustard; TAX¼paclitaxel; L-OHP¼oxaliplatin; MMC¼mi-
mitomycin-C.
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Figure 3 Relative in vitro activity of topotecan vs irinotecan. A scatterplot
of the 50% lethal concentration values for topotecan and irinotecan in 239
tumour biopsy samples. A correlation coefficient of 0.54 indicates significant
correlation between the antitumour activity of topotecan and irinotecan in
vitro (Po0.0005).
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sspecimens. This suggests that NSCLC may be more sensitive to
single-agent topotecan than prostate cancers.
Several phase II trials have investigated the use of topotecan in
the treatment of advanced NSCLC. Perez-Soler et al (1996) and
Weitz et al (2000) reported overall response rates of 15 and 16%,
respectively, in patients treated with topotecan, and Lynch et al
(1994) reported stable disease in 55%. In contrast, and consistent
with the results of the current study, single-agent topotecan has
shown less promise in patients with metastatic, hormone-
refractory prostate cancer (Hudes et al, 1995). The synergy results
for prostate and other cancers may nonetheless offer fertile
avenues for future investigations with topotecan. A possible
explanation for the difference between in vitro and in vivo activity
of single-agent topotecan in NSCLC is a pharmacokinetic effect.
The inherent activity (reflected ex vivo) for topoisomerase I
inhibitors may not be optimally exploited using current admin-
istration schedules. Recent observations with alternative schedules
– including oral, long-term i.v., or the weekly administration of
topotecan – suggest that these regimens may prove superior to the
current 5-day topotecan schedules in those diseases that are most
inherently sensitive to topotecan, with NSCLC appearing to be an
attractive target.
In our study, several topotecan combinations demonstrated
synergy. Among the most active combinations was that of
topotecan plus 5-FU in breast cancer, which demonstrated synergy
in 57% of specimens. It must be noted that the degree of synergy
(combinatorial advantage) is independent of the relative anti-
tumour activity (i.e. LC50). However, synergy, defined as
pharmacologic supraadditivity, may occur at LC50 values that
have no clinical relevance. Therefore, it is advantageous to
examine the degree of synergy in the context of the relative
activity, and Z-scores facilitate this comparison. The Z-score for
topotecan/5-FU in breast cancer fell in the sensitive range. Based
on both synergy and sensitivity (by Z-score) findings for this
combination in breast cancer patients, a phase II clinical trial has
been initiated (phase II study of topotecan plus capecitabine for
recurrent, locally advanced or metastatic breast cancer). This study
will examine the clinical activity of this combination and correlate
clinical response with ex vivo results for each patient.
To date, breast cancer has not been a target for topotecan
therapy. Levine et al (1999) reported a response rate of 10% in a
study of topotecan in relapsed breast cancer conducted by the
Cancer and Leukaemia Group B. However, Japanese investigators
reported a 23% response rate for the closely related irinotecan in
patients with advanced breast cancer (Taguchi et al, 1994). The
irinotecan schedules (based on weekly dosing) compared with the
topotecan schedules (based on consecutive 5-day dosing) may, in
part, explain the differences in overall response rates. By
modifying the topotecan schedule to days 1 and 8, we more
closely approximate the irinotecan administration schedule in our
current study. The concordance between irinotecan and topotecan
observed in our parallel analyses suggest that future ex vivo
analyses could compare topotecan with other topoisomerase I
inhibitors (e.g. 9-aminocamptothecin or 9-nitrocamptothecin).
Several topotecan combinations demonstrated synergy in
NSCLC specimens, including topotecan/mitomycin-C (38%) and
topotecan/cisplatin (31%). Both combinations revealed favourable
Z-scores. Preliminary results for topotecan/cisplatin in NSCLC
patients have provided overall response rates ranging from 14 to
31% (Raymond et al, 1997; Wiesenfeld et al, 1997). The high
incidence of haematologic and nonhaematologic toxicity limited
the use of this combination. Alternate dosing schedules for
topotecan/cisplatin, or the substitution of carboplatin for cisplatin,
might prove more tolerable. A phase II study of topotecan/
carboplatin in NSCLC patients provided a clinical benefit in 49% of
patients and a 1-year survival rate of 32% (Pujol et al, 2001). No
episodes of nephrotoxicity, ototoxicity, or neurotoxicity were
reported. Although synergy was demonstrated in o20% of
specimens in NSCLC for topotecan/vinorelbine, the Z-scores for
this combination, and those for topotecan/gemcitabine, fell within
the sensitive range. Vinorelbine provides single-agent activity with
overall response rates ranging from 12 to 20% in NSCLC (Crawford
et al, 1996; The Elderly Lung Cancer Vinorelbine Italian Study
Group, 1999). The ex vivo results revealing activity for topotecan/
vinorelbine in NSCLC are consistent with the report of Stupp et al
(2001), which provided a response rate of 42% in NSCLC patients
treated with this combination
Ex vivo activity profiles also provide the opportunity to develop
novel triplet regimens. The favourable activity observed for the
doublets of topotecan plus cisplatin and topotecan plus gemcita-
bine paralleled our ex vivo results for the three-drug combination
in NSCLC specimens (unpublished observations). Guarino et al
(2002) reported a 38% objective response rate and 1-year survival
of 33% in patients with NSCLC who received this weekly regimen.
Toxicity was extremely mild with only one of 30 patients
experiencing a grade IV adverse event (leukopenia). A second
phase II trial is under final development to further evaluate this
triplet in NSCLC (phase II study of hycamtin, cisplatinum, and
gemcitabine in advanced NSCLC).
Several other observations were of interest. Despite the low
single-agent activity of topotecan in prostate cancer specimens, the
favourable degrees of synergy and activity for topotecan/cisplatin
in this disease could provide insights for future investigation. On
the contrary, the high degree of synergy for topotecan/mitomycin-
C in colon cancer specimens when combined with the resistant Z-
score for this combination in colon specimens argues against
clinical evaluation. Although single-agent topotecan is widely used
for the treatment of relapsed ovarian cancer, combinations
identified in this study may offer additional insights. The high
degree of synergy that we reported previously for topotecan/
gemcitabine in ovarian cancer specimens (Su et al, 2001) is
supported by the results of a phase II study, in which seven of 11
(64%) patients with relapsed ovarian cancer achieved objective
responses with this combination (Sehouli et al, 2001). Topotecan
combinations might also be investigated in diseases that are
historically resistant to chemotherapy. Fiorica et al (2002) reported
a 28% (nine of 32) overall response rate for topotecan/cisplatin in
patients with recurrent cervical cancer.
In summary, topotecan reveals activity in human NSCLC and in
breast, prostate, and colon cancer primary cultures. Previously,
unrecognised synergy between topotecan and other agents have
allowed the development of novel phase II clinical trials in NSCLC
and breast cancers. Trials are also in development to evaluate
topotecan in cervical, colorectal, prostate, and haematologic
malignancies.
ACKNOWLEDGEMENTS
We acknowledge the technical assistance of Craig Chou, Yong
Zhuang Su, Cheryl Kollin Dorothy Horlick. This work was
supported by GlaxoSmithKline, Philadelphia, PA, USA. We grate-
fully acknowledge the financial support of GlaxoSmithKline
(Philadelphia, PA, USA).
REFERENCES
Ardizzoni A, Hansen H, Dombernowsky P, Gamucci T, Kaplan S, Postmus
P, Giaccone G, Schaefer B, Wanders J, Verweij J (1997) Topotecan, a new
active drug in the second-line treatment of small-cell lung cancer: a
phase II study in patients with refractory and sensitive disease. J Clin
Oncol 15: 2090–2096
Topotecan activity in solid tumour cultures
RA Nagourney et al
1793
British Journal of Cancer (2003) 89(9), 1789–1795 & 2003 Cancer Research UK
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
sArdizzoni A, Manegold C, Gaafar R, Buchholdz E, Debruyne C, Damen S,
Curran D, King K, Giaccone G (1999) Combination chemotherapy with
cisplatin and topotecan as second-line treatment of sensitive (S) and
refractory (R) small cell lung cancer (SCLC): an EORTC LCCG phase II
study (abstract). Proc Am Soc Clin Oncol 18: 471a
Beran M, Estey E, O’Brien SM, Giles FJ, Koller CA, Kornblau S, Keating M,
Kantarjian HM (1998) Results of topotecan single-agent therapy in
patients with myelodysplastic syndromes and chronic myelomonocytic
leukemia. Leukemia Lymphoma 31: 521–531
Bookman MA, Malmstro ¨m H, Bolis G, Gordon A, Lissoni A, Krebs JB,
Fields SZ (1998) Topotecan for the treatment of advanced epithelial
ovarian cancer: an open-label phase II study in patients treated after
prior chemotherapy that contained cisplatin or carboplatin and
paclitaxel. J Clin Oncol 16: 3345–3352
Bosanquet AG, Johnson SA, Richards SM (1999) Prognosis for fludarabine
therapy of chronic lymphocytic leukaemia based on ex vivo drug
response by DISC assay. Br J Haematol 106: 71–77
Brown III JV, Peters III WA, Rettenmaier MA, Karlan BY, Dillman RA,
Smith MR, Drescher CW, Micha JP (2000) A phase I trial of a 3-day
topotecan q 21 days for recurrent epithelial cancers of the ovary,
fallopian tube, and peritoneum. Gynecol Oncol 79: 495–498
Burke TG, Mi Z (1994) The structural basis of camptothecin interactions
with human serum albumin: impact on drug stability. J Med Chem 37:
40–46
Cheadle C, Vawter MP, Freed WJ, Becker KG (2003) Analysis of microarray
data using Z score transformation. J Mol Diagn 5: 73–81
Chou T-C, Talalay P (1987) Applications of the median-effect principle for
the assessment of low-dose risk of carcinogens and for the quantitation
of synergism and antagonism of chemotherapeutic agents. In New
Avenues in Developmental Cancer Chemotherapy Harrap KR, Connors
TA (eds) pp 37–64. Orlando, FL: Academic Press Inc.
Clarke-Pearson DL, Van Le L, Iveson T, Whitney CW, Hanjani P,
Kristensen G, Malfetano JH, Beckman RA, Ross GA, Lane SR, DeWitte
MH, Fields SZ (2001) Oral topotecan as single-agent second-line
chemotherapy in patients with advanced ovarian cancer. J Clin Oncol
19: 3967–3975
Cortazar P, Johnson BE (1999) Review of the efficacy of individualized
chemotherapy selected by in vitro drug sensitivity testing for patients
with cancer. J Clin Oncol 17: 1625–1631
Crawford J, O’Rourke M, Schiller JH, Spiridonidis CH, Yanovich S, Ozer H,
Langleben A, Hutchins L, Koletsky A, Clamon G, Burman S, White R,
Hohneker J, Spiridonidis CH (1996) Randomized trial of vinorelbine
compared with fluorouracil plus leucovorin in patients with stage IV
non-small-cell lung cancer. J Clin Oncol 14: 2774–2784
Creemers GJ, Bolis G, Gore M, Scarfone G, Lacave AJ, Guastalla JP, Despax
R, Favalli G, Kreinberg R, Van Belle S, Hudson I, Verweij J, ten Bokkel
Huinink WW (1996) Topotecan, an active drug in the second-line
treatment of epithelial ovarian cancer: results of a large European phase
II study. J Clin Oncol 14: 3056–3061
Depierre A, von Pawel J, Hans K, Moro D, Clark P, Gatzemeier U, Paillot N,
Scheithauer W, Carmichael J, Santoro A, Ross G, Marangolo M (1997)
Evaluation of topotecan (Hycamtin
t) in relapsed small cell lung cancer
(SCLC). A multicentre phase II study (abstract). Lung Cancer 18(Suppl.
1): 35
Eckardt J, Gralla R, Palmer MC, Gandara D, Laplante J, Sandler A, Fields
SZ, Fitts D, Broom C (1996) Topotecan (T) as second-line therapy in
patients (Pts) with small cell lung cancer (SCLC): a phase II study
(abstract). Ann Oncol 7(Suppl. 5): 107
Feinstein AR (1998) Clinical Epidemiology: The Architecture of Clinical
Research. Philadelphia: W.B. Sanders
Fiorica J, Holloway R, Ndubisi B, Orr J, Grendys E, Boothby R, DeCesare S,
LaPolla J, Hoffman M, Patel J (2002) Phase II trial of topotecan and
cisplatin in persistent or recurrent squamous and nonsquamous
carcinomas of the cervix. Gynecol Oncol 85: 89–94
Frasci G, Panza N, Comella P, Carteni G, Guida T, Nicolella GP, Natale M,
Lombardi R, Apicella A, Pacilio C, Gravina A, Lapenta L, Comella G
(1999) Cisplatin–topotecan–paclitaxel weekly administration with G-
CSF support for ovarian and small-cell lung cancer patients: a dose-
finding study. Ann Oncol 10: 355–358
Guarino MJ, Schneider CJ, Grubbs SS, Biggs DD, Himelstein AL, Hogaboom
K, Tilak S (2002) A dose-escalation study of weekly topotecan, cisplatin,
and gemcitabine front-line therapy in patients with inoperable non-small
cell lung cancer. Oncologist 7: 509–515
Hainsworth JD, Burris III HA, Morrissey LH, Greco FA (1999) Phase I trial
of paclitaxel, carboplatin, and topotecan with or without filgrastim
(granulocyte-colony stimulating factor) in the treatment of patients with
advanced, refractory cancer. Cancer 85: 1179–1185
Hays WL (1994) Statistics 5th edn. International Thomson Publishing.
Hochster H, Wadler S, Runowicz C, Liebes L, Cohen H, Wallach R, Sorich J,
Taubes B, Speyer J (1999) Activity and pharmacodynamics of 21-day
topotecan infusion in patients with ovarian cancer previously treated
with platinum-based chemotherapy. J Clin Oncol 17: 2553–2561
Homesley HD, Hall DJ, Martin DA, Lewandowski GS, Vaccarello L, Nahhas
WA, Suggs CL, Penley RG (2001) A dose-escalating study of weekly bolus
topotecan in previously treated ovarian cancer patients. Gynecol Oncol
83: 394–399
Hoskins P, Eisenhauer E, Beare S, Roy M, Drouin P, Stuart G, Bryson P,
Grimshaw R, Capstick V, Zee B (1998) Randomized phase II study of two
schedules of topotecan in previously treated patients with ovarian
cancer: a National Cancer Institute of Canada Clinical Trials Group
study. J Clin Oncol 16: 2233–2237
Hudes GR, Kosierowski R, Greenberg R, Ramsey HE, Fox SC, Ozols RF,
McAleer CA, Giantonio BJ (1995) Phase II study of topotecan in
metastatic hormone-refractory prostate cancer. Invest New Drugs 13:
235–240
Jacobs SA, Jett JR, Belani CP, Long GS, Day RD, Kim HD, Levitt ML,
Woolley PV (1999) Topotecan and paclitaxel, an active couplet, in
untreated extensive disease small cell lung cancer (abstract). Proc Am Soc
Clin Oncol 18: 470a
Kingsbury WD, Boehm JC, Jakas DR, Holden KG, Hecht SM, Gallagher G,
Caranfa MJ, McCabe FL, Faucette LF, Johnson RK, Hertzberg RP (1991)
Synthesis of water-soluble (aminoalkyl) camptothecin analogues: inhibi-
tion of topoisomerase I and antitumor activity. J Med Chem 34: 98–107
Kirk RE (1982) Experimental Design: Procedure for The Behavorial Sciences.
Pacific Grove, CA: Brooks/Cole Publishing Company
Kudelka AP, Tresukosol D, Edwards CL, Freedman RS, Levenback C,
Chantarawiroj P, Gonzalez de Leon C, Kim EE, Madden T, Wallin B,
Hord M, Verschraegen C, Raber M, Kavanagh JJ (1996) Phase II study of
intravenous topotecan as a 5-day infusion for refractory epithelial
ovarian carcinoma. J Clin Oncol 14: 1552–1557
Lemkin PF, Thornwall CG, Walton KD, Hennighausen L. (2000)
Themicroarray explorer to for data mining of cDNA microarrays:
application for the mammary gland. Nucleic Acids Res 28: 4452–4459
Levine G (1991) A Guide to SPSS for Analysis of Variance. Hove: Lawrence
Erlbaum Associates
Levine EG, Cirrincione CT, Szatrowski TP, Canellos G, Norton L,
Henderson IC (1999) Phase II trial of topotecan in advanced breast
cancer: a Cancer and Leukemia Group B study. Am J Clin Oncol 22: 218–
222
Lynch Jr TJ, Kalish L, Strauss G, Elias A, Skarin A, Shulman LN, Posner M,
Frei III E (1994) Phase II study of topotecan in metastatic non-small-cell
lung cancer. J Clin Oncol 12: 347–352
McGuire WP, Blessing JA, Bookman MA, Lentz SS, Dunton CJ (2000)
Topotecan has substantial antitumor activity as first-line salvage therapy
in platinum-sensitive epithelial ovarian carcinoma: a Gynecologic
Oncology Group Study. J Clin Oncol 18: 1062–1067
Nagourney R, Brewer C, Radecki S, Kidder W, Sommers B, Evans S, Minor
D, DiSaia PJ (2003) A phase II trial of gemcitabine plus cisplatin
repeating doublet therapy in previously treated, relapsed ovarian cancer
patients. Gynecol Oncol 88: 35–39
Nagourney RA, Link JS, Blitzer JB, Forsthoff C, Evans SS (2000)
Gemcitabine plus cisplatin repeating doublet therapy in previously
treated, relapsed breast cancer patients. J Clin Oncol 18: 2245–2249
O’Neill P, Clark PI, Smith D, Marshall E, Hannigan K, Ross G (2001) A
phase I trial of a 5-day schedule of intravenous topotecan and etoposide
in previously untreated patients with small-cell lung cancer. Oncology
61(Suppl. 1): 25–29
Perez-Soler R, Fossella FV, Glisson BS, Lee JS, Murphy WK, Shin DM,
Kemp BL, Lee JJ, Kane J, Robinson RA, Lippman SM, Kurie JM, Huber
MH, Raber MN, Hong WK (1996) Phase II study of topotecan in patients
with advanced non-small-cell lung cancer previously untreated with
chemotherapy. J Clin Oncol 14: 503–513
Pujol JL, von Pawel J, Tumolo S, Martoni A, Hearn S, Fields SZ, Ross G
(2001) Preliminary results of combined therapy with topotecan and
carboplatin in advanced non-small-cell lung cancer. Oncology 61(Suppl.
1): 47–54
Raymond E, Burris HA, Rowinsky EK, Eckardt JR, Rodriguez G, Smith L,
Weiss G, Von Hoff DD (1997) Phase I study of daily times five topotecan
and single injection of cisplatin in patients with previously untreated
non-small-cell lung carcinoma. Ann Oncol 8: 1003–1008
Topotecan activity in solid tumour cultures
RA Nagourney et al
1794
British Journal of Cancer (2003) 89(9), 1789–1795 & 2003 Cancer Research UK
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
sReed JC (1999) Dysregulation of apoptosis in cancer. J Clin Oncol 17: 2941–
2953
Rothenberg ML (1997) Topoisomerase I inhibitors: review and update. Ann
Oncol 8: 837–855
Sehouli J, Lichtenegger W, Hindenburg HJ, Klare P, Keil E, Heinrich G,
Elling D, Hieronimus-Reichel A, Oskay G, Blohmer J, Camara O, Ledwon
P, Stengel D (2001) A phase II study of topotecan plus gemcitabine in the
treatment of patients with relapsed ovarian cancer after failure of first-
line chemotherapy with platin and paclitaxel (abstract). Proc Am Soc Clin
Oncol 20: 216a
Shi LM, Myers TG, Fan Y, O’Connor PM, Paull KD, Friend SH, Weinstein
JN (1998) Mining the National Cancer Institute anticancer drug
discovery database: cluster analysis of ellipticine analogs with p53-
invese and central nervous system-selective patterns of activity. Mol
Pharmacol 53: 241–251
Stupp R, Bodmer A, Duvoisin B, Bauer J, Perey L, Bakr M, Ketterer N,
Leyvraz S (2001) Is cisplatin required for the treatment of non-small-cell
lung cancer. Experience and preliminary results of a phase I/II trial with
topotecan and vinorelbine. Oncology 61(Suppl. 1): 35–41
Su Y-Z, Sommers B, Horlick D, Harris C, Evans S, Nagourney R (2001)
Synergy between topotecan and other cytotoxic drugs in human tumors
(abstract). Proc Am Assoc Cancer Res 42: 253–254
Taguchi T, Tominaga T, Ogawa M, Ishida T, Morimoto K, Ogawa N (1994)
A late phase II study of CPT-11 (irinotecan) in advanced breast cancer.
CPT-11 Study Group on Breast Cancer). Gan To Kagaku Ryoho 21:
1017–1024
ten Bokkel Huinink W, Gore M, Carmichael J, Gordon A, Malfetano J,
Hudson I, Broom C, Scarabelli C, Davidson N, Spanczynski M, Bolis G,
Malmstro ¨m H, Coleman R, Fields SC, Heron JF (1997) Topotecan versus
paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin
Oncol 15: 2183–2193
The Elderly Lung Cancer Vinorelbine Italian Study Group (1999) Effects of
vinorelbine on quality of life and survival of elderly patients with
advanced non-small-cell lung cancer. J Natl Cancer Inst 91: 66–72
Verweij J, Lund B, Beijnen J, Planting A, de Boer-Dennert M, Koier I,
Rosing H, Hansen H (1993) Phase I and pharmacokinetics study of
topotecan, a new topoisomerase I inhibitor. Ann Oncol 4: 673–678
von Pawel J, Gatzemeier U, Pujol JL, Moreau L, Bildat S, Ranson M,
Richardson G, Steppert C, Riviere A, Camlett I, Lane S, Ross G (2001)
Phase II comparator study of oral versus intravenous topotecan in
patients with chemosensitive small-cell lung cancer. J Clin Oncol 19:
1743–1749
von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, Chrysson
NG, Stewart DJ, Clark PI, Palmer MC, Depierre A, Carmichael J, Krebs JB,
Ross G, Lane SR, Gralla R (1999) Topotecan versus cyclophosphamide,
doxorubicin, and vincristine for the treatment of recurrent small-cell
lung cancer. J Clin Oncol 17: 658–667
Wall JG, Burris III HA, Von Hoff DD, Rodriguez G, Kneuper-Hall R, Shaffer
D, O’Rourke T, Brown T, Weiss G, Clark G, McVea S, Brown J, Johnson
R, Friedman C, Smith B, Mann WS, Kuhn J (1992) A phase I clinical and
pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F
104864) given as an intravenous bolus every 21 days. Anticancer Drugs 3:
337–345
Weitz JJ, Marschke Jr RF, Sloan JA, Grill JP, Jett JR, Knost JA, Hatfield AK,
Zenk DW, Bate WW, Schaefer PL (2000) A randomized phase II trial of
two schedules of topotecan for the treatment of advanced stage non-
small cell lung cancer. Lung Cancer 28: 157–162
Wiesenfeld M, Marks R, Grill J, Sloan J, Tazelaar H, Carroll T, Kugler J,
Krook J (1997) A randomized phase II study of topotecan (TOPA) and
cisplatin (CDDP) with filgrastim (G-CSF) versus topotecan and paclitaxel
(Taxol
s) with filgrastim in patients with advanced non-small cell lung
cancer (abstract). Proc Am Soc Clin Oncol 16: 488a
Topotecan activity in solid tumour cultures
RA Nagourney et al
1795
British Journal of Cancer (2003) 89(9), 1789–1795 & 2003 Cancer Research UK
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
s